Clinical TrialJul 1, 2026, 07:01 AM
iBio's IBIO-610 shows 98% Activin E inhibition in preclinical study
AI Summary
iBio, Inc. announced new preclinical data for its Activin E antibody candidate, IBIO-610, in obese non-human primates. A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E, sustained for eight weeks. When combined with semaglutide, IBIO-610 demonstrated greater visceral and total fat loss while reducing lean mass loss by 73% compared to semaglutide alone. These findings support IBIO-610's potential as a differentiated, long-acting therapy for obesity, with the full data to be presented at the 2026 EASD Annual Meeting.
Key Highlights
- Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E.
- Activin E inhibition was sustained through eight weeks in obese NHPs.
- IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.
- Combined with semaglutide, IBIO-610 drove greater visceral and total fat loss.
- Full preclinical dataset to be presented at the EASD Annual Meeting (Sept 28 – Oct 2).
Price Impact
More from IBIO